🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “The First People's Hospital of Lianyungang” Clear

  1. HER2 Tumor Vaccine

    The First People's Hospital of Lianyungang

    Adenocarcinoma - GEJ

    phase 1 mab active

    1 trial

  2. HSK3486

    The First People's Hospital of Lianyungang

    Healthy Elderly Subjects

    phase 1 small molecule completed

    1 trial

  3. HSK3486

    The First People's Hospital of Lianyungang

    Chronic Renal Impairment

    phase 1 small molecule completed

    1 trial

  4. HY-2003 (10 mg/ml), BELKYRA and placebo

    The First People's Hospital of Lianyungang

    Moderate or Severe Submental Fullness

    phase 1 small molecule active

    1 trial

  5. Hema-NeoTIL01

    The First People's Hospital of Lianyungang

    Leukemia, Myeloid, Acute

    phase 1 mab active

    1 trial

  6. Human BCMA targeted T Cells Injection

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  7. Human Umbilical Mesenchymal Stem Cells

    The First People's Hospital of Lianyungang

    Osteoarthritis, Knee

    phase 1 mab active

    1 trial

  8. Human amniotic-derived mesenchymal stem cells

    The First People's Hospital of Lianyungang

    Chronic Kidney Diseases

    phase 1 mab active

    1 trial

  9. Hydronidone capsules

    The First People's Hospital of Lianyungang

    Liver Fibrosis

    phase 1 small molecule active

    1 trial

  10. IBR733 Cell Injection

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  11. ICI201

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

  12. JWCAR129

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    phase 1 mab active

    1 trial

  13. JY306 universal NK cell injection

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Hematological Malignancies

    phase 1 mab active

    1 trial

  14. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  15. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Cancer

    phase 1 small molecule active

    1 trial

  16. Keverprazan

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    phase 1 small molecule active

    1 trial

  17. LUCAR-E9D or LUCAR-E9K cells product

    The First People's Hospital of Lianyungang

    B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

    phase 1 mab active

    1 trial

  18. LUCAR-G39P cells product

    The First People's Hospital of Lianyungang

    Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 mab terminated

    1 trial

  19. LVIVO-TaVec200 product

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  20. LY007

    The First People's Hospital of Lianyungang

    B-NHL

    phase 1 small molecule active

    1 trial

  21. Lansoprazole capsules

    The First People's Hospital of Lianyungang

    Effect of Drugs

    phase 1 small molecule completed

    1 trial

  22. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  23. Light Power Density and Light Duration 40 mW/cm²*1000s

    The First People's Hospital of Lianyungang

    Healthy Adult Subjects

    phase 1 other completed

    1 trial

  24. Low dose ET019002- T Cells

    The First People's Hospital of Lianyungang

    B-Cell Malignancies

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources